Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 9, Pages 4774
Publisher
MDPI AG
Online
2021-04-30
DOI
10.3390/ijms22094774
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trastuzumab Modulates the Protein Cargo of Extracellular Vesicles Released by ERBB2+ Breast Cancer Cells
- (2021) Silvia Marconi et al. Membranes
- Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
- (2020) Shanu Modi et al. JOURNAL OF CLINICAL ONCOLOGY
- 138O CNS metastases in HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan: DESTINY-Breast01 subgroup analyses
- (2020) G. Jerusalem et al. ANNALS OF ONCOLOGY
- Trastuzumab Deruxtecan: First Approval
- (2020) Susan J. Keam DRUGS
- Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.
- (2020) Egbert F. Smit et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).
- (2020) Kohei Shitara et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis.
- (2020) Shanu Modi et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
- (2020) Salvatore Siena et al. JOURNAL OF CLINICAL ONCOLOGY
- Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
- (2020) Nancy U. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
- (2020) Junji Tsurutani et al. Cancer Discovery
- HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
- (2020) Bob T. Li et al. Cancer Discovery
- O-11 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)
- (2020) K. Yamaguchi et al. ANNALS OF ONCOLOGY
- Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars
- (2020) Megan E. Tesch et al. DRUGS
- Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease
- (2020) Larissa Di Villeneuve et al. Frontiers in Oncology
- Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
- (2019) Funda Meric-Bernstam et al. LANCET ONCOLOGY
- Afatinib in non-small cell lung cancer with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP)
- (2019) Rafal Dziadziuszko et al. Journal of Thoracic Oncology
- [fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification
- (2019) Naoki Takegawa et al. INTERNATIONAL JOURNAL OF CANCER
- Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
- (2019) Kohei Shitara et al. LANCET ONCOLOGY
- Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
- (2019) Kenji Tamura et al. LANCET ONCOLOGY
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
- (2019) Rashmi K. Murthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
- (2018) S Siena et al. ANNALS OF ONCOLOGY
- Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3
- (2018) Jeffrey S. Ross et al. CANCER
- Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
- (2018) Bob T. Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
- (2018) Alexey A. Larionov Frontiers in Oncology
- Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment
- (2018) Adrianus J. de Langen et al. BRITISH JOURNAL OF CANCER
- Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
- (2018) Josep Tabernero et al. LANCET ONCOLOGY
- Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET ONCOLOGY
- Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
- (2017) Toshihiko Doi et al. LANCET ONCOLOGY
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
- (2016) Andrea Sartore-Bianchi et al. LANCET ONCOLOGY
- Therapeutic implication of HER2 in advanced biliary tract cancer
- (2016) Ah-Rong Nam et al. Oncotarget
- Lung cancer patients withHER2mutations treated with chemotherapy andHER2-targeted drugs: results from the European EUHER2 cohort
- (2015) J. Mazières et al. ANNALS OF ONCOLOGY
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
- (2014) Carlos L. Arteaga et al. CANCER CELL
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
- (2013) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung
- (2012) Tobias J Grob et al. MODERN PATHOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers
- (2010) Andreas H. Marx et al. HUMAN PATHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started